Publications
ARROW publications and presentations - May 2012
Publications from the DART trial are available on the DART website.
1)P Nahirya-Ntege, A Cook, T Vhembo, W Opilo, R Namuddu, R Katuramu, J Tezikyabbiri, B Naidoo-James, D Gibb, on behalf of the ARROW Trial Team. Young HIV-Infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa. PloS ONE 7(5): e36186. doi:10.1371/journal.pone.0036186
2) P Kasirye, L Kendall, KK Adkison, C Tumusiime, M Ssenyonga, S Bakeera-Kitaka, P Nahirya-Ntege, T Mhute, A Kekitiinwa, W Snowden, DM Burger, DM Gibb, AS Walker on behalf of the ARROW trial team. Pharmacokinetics of oral solution versus tablet formulation varies with antiretroviral drug in the target population of HIV-1 infected children. Clinical Pharmacology and Therapeutics 2011 Dec 21;10.1038/clpt.2011.225
3) Q Fillekes, E Natukunda, J Balungi, L Kendall, M Bwakura-Dangarembizi, R Keishanyu, A Ferrier, J Lutakome, DM Gibb, DM Burger, AS Walker on behalf of the ARROW trial team. Paediatric under-dosing of Efavirenz: a pharmacokinetic study in Uganda. Journal of Acquired Immune Deficiency Syndromes 2011 Dec 1;58(4):392-8.
4) A Prendergast, M Bwakura-Dangarembizi, A Cook, S Bakeera-Kitaka, E Natukunda, P Nahirya, K Nathoo, C Karungi, J Lutaakome, A Kekitiinwa, D M Gibb. Acute kwashiorkor in HIV-infected African children starting antiretroviral therapy in the ARROW trial. AIDS 2011 Apr 24;25(7):951-6
5) P Nahirya-Ntege, V Musiime, B Naidoo, S Bakeera-Kitaka, K Nathoo, P Munderi, P Mugyenyi, A Kekitiinwa, MF Bwakura-Dangarembizi, J Crawley on behalf of the ARROW trial team. Low incidence of abacavir hypersensitivity reaction among African children initiating antiretroviral therapy. Paediatric Infectious Disease Journal
10.1097/INF.0b013e3182076864
6) V Musiime, L Kendall, S Bakeera-Kitaka, W Snowden, F Odongo, M Thomason, P Musoke, K Addison, David Burger, P Mugyenyi, A Kekitiinwa, DM Gibb, AS Walker on behalf of the ARROW trial team. Pharmacokinetics and acceptability of once versus twice daily lamivudine and abacavir in HIV-1 infected Ugandan children in the ARROW trial. Antiviral Therapy 10.3851/IMP1695.
Posters
1. Weight gain in children initiating ART is not increased by nutritional supplements.19th Conference on retroviruses and opportunistic infections, 5-8 March 2012, Seattle, Washington
2. Long term profiles of CD4 reconstitution in HIV-infected Children initiating Antiretroviral Therapy in Uganda and Zimbabwe.19th Conference on retroviruses and opportunistic infections, 5-8 March 2012, Seattle, Washington.
3. Bacteriology of ear discharge in HIV-infected children on ART in the ARROW trial in Uganda and Zimbabwe.3rd International Workshop on HIV Paediatrics, 15 – 16 July 2011 / 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 17 – 20 July 2011, Rome, Italy
4. Bacteraemia in HIV-1 infected children on antiretroviral therapy in Uganda and Zimbabwe in the ARROW clinical trial.6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 17 – 20 July 2011, Rome, Italy
5. PK of ZDV dosed twice-daily according to who weight-bands in African hiv-1-infected children.18th Conference on retroviruses and opportunistic infections, 27 February – 2 March 2011, Boston, Massachusetts
6. CD4 T cell depletion, and not age, drives reconstitution within CD4 cell compartments in HIV-infected children initiating ART in Uganda.18th Conference on retroviruses and opportunistic infections, 27 February – 2 March 2011, Boston, Massachusetts
7. Pharmacokinetics of lamivudine, abacavir and Zidovudine administered twice-daily as syrups versus Scored tablets in HIV-1 infected Ugandan children.Tenth International Congress on Drug Therapy in HIV Infection, 7 - 11 November 2010, Glasgow, United Kingdom
8. Tablets are more acceptable and give fewer problems than syrups among young HIV-infected children in resource limited settings in the ARROW trial.2nd International Workshop on HIV Paediatrics, 16 – 17 July 2010 and XVIII International AIDS Conference, 18 – 23 July 2010, Vienna, Austria
9. Disclosure of their HIV status to HIV-infected children participating in the ARROW trial in Entebbe, Uganda.2nd International Workshop on HIV Paediatrics, 16 – 17 July 2010 and XVIII International AIDS Conference, 18 – 23 July 2010, Vienna, Austria
10. CD4 depletion, and not age, may be a driver of abnormal CD4 cell compartments in HIV-infected children initiating ART in Uganda.17th Conference on retroviruses and opportunistic infections, 16 – 19 February 2010, San Francisco, California
11. Pharmacokinetics of Efavrinez dosed according to the WHO weight-bands in children in Uganda.17th Conference on retroviruses and opportunistic infections, 16 – 19 February 2010, San Francisco, California
12. Successful management of suspected Abacavir HSRs in African children5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22 July 2009, Cape Town, South Africa / 1st International Workshop on HIV Pediatrics, 17-18 July 2009, Cape Town, South Africa
13. HIV-status and healthcare needs of primary caregivers of HIV-infected children in Zimbabwe5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22 July 2009, Cape Town, South Africa
14. Acute kwashiorkor soon after initiating ART among HIV infected children5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22 July 2009, Cape Town, South Africa / 1st International Workshop on HIV Pediatrics, 17-18 July 2009, Cape Town, South Africa
15. PK of Once versus Twice Daily Lamivudine and Abacavir in HIV-1 Infected Ugandan Children5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22 July 2009, Cape Town, South Africa / 1st International Workshop on HIV Pediatrics, 17-18 July 2009, Cape Town, South Africa
16. Confidentiality and non-disclosure can affect enrolment, follow-up and adherence to ARTXVII International AIDS Conference, 3-8 August 2008, Mexico City
17. ARROW study design and baseline characteristicsXVII International AIDS Conference, 3-8 August 2008, Mexico City
18. Ethical and practical constraints to the participation of HIV-infected orphaned children in a clinical trial in ZimbabweXVII International AIDS Conference, 3-8 August 2008, Mexico City
Oral
1. Bacteriology of ear discharge in HIV-infected children on ART in the ARROW trial in Uganda and Zimbabwe.5th National Paediatric HIV and AIDS Conference, 29 September 2011, Kampala Uganda
2. Bacteraemia in HIV-1 infected children on antiretroviral therapy in Uganda and Zimbabwe in the ARROW clinical trial.3rd International Workshop on HIV Paediatrics, 15 – 16 July 2011, Rome, Italy
3. Early mortality following ART initiation in HIV-infected adults and children in Uganda and Zimbabwe.Tenth International Congress on Drug Therapy in HIV Infection, 7 - 11 November 2010, Glasgow, United Kingdom
4. CD4 depletion, and not age, may be a driver of abnormal CD4 cell compartments in HIV-infected children initiating ART in Uganda.4th National Paediatric HIV/AIDS conference, 28 – 30 September 2010, Kampala, Uganda
5. Tablets are more acceptable and give fewer problems than syrups among young HIV-infected children in resource limited settings in the ARROW trial.4th National Paediatric HIV/AIDS conference, 28 – 30 September 2010, Kampala, Uganda
6. Comparison between calculated and direct measurements of CD4 percentage for immunological monitoring of antiretroviral therapy in children.4th National Paediatric HIV/AIDS conference, 28 – 30 September 2010, Kampala, Uganda
7. Disclosure of their HIV status to HIV-infected children participating in the ARROW trial in Entebbe, Uganda.4th National Paediatric HIV/AIDS conference, 28 – 30 September 2010, Kampala, Uganda
8. Pharmacokinetics of Efavrinez dosed according to the WHO weight-bands in children in Uganda.4th National Paediatric HIV/AIDS conference, 28 – 30 September 2010, Kampala, Uganda
